Evidence-based research on mycotoxin exposure, Chronic Inflammatory Response Syndrome, and detox protocols, from HLA-DR genetics and biotoxin pathways to binder strategies and immune recovery.
Follow a structured route from exposure questions to symptom patterns, testing conversations, environmental action, and recovery support.
Select the patterns you recognize. The tool helps organize questions; it cannot confirm exposure or diagnose CIRS.
Read the core guide
Start with the main MyBioHack overview, then branch into mechanisms and testing.
Open articleAsk from your pattern
Ask a broad question, then refine it with the Bot.
Talk to the BotWork with Jacob
Book a consultation and bring a focused history and testing question list.
Start a consultationNo supplement can compensate for ongoing exposure. Recovery starts with environment, not binders.
Chronic Inflammatory Response Syndrome (CIRS) is a multi-system, multi-symptom illness caused by exposure to biotoxins, most commonly from water-damaged buildings containing mold species like Stachybotrys chartarum, Aspergillus, Penicillium, and Chaetomium. These organisms produce mycotoxins, volatile organic compounds, and beta-glucans that trigger a devastating inflammatory cascade in genetically susceptible individuals.
The key genetic factor is HLA-DR haplotype. Approximately 24% of the population carries HLA-DR genotypes that prevent the immune system from recognizing and clearing biotoxins. In these individuals, mycotoxins are not tagged for removal. They recirculate endlessly, triggering the innate immune system to produce inflammatory cytokines in a self-perpetuating loop.
The biotoxin pathway, mapped by Dr. Ritchie Shoemaker, describes the cascade: mycotoxin exposure leads to cytokine elevation, which suppresses melanocyte-stimulating hormone and vasoactive intestinal peptide, disrupts antidiuretic hormone and osmolality regulation, elevates MMP-9 and TGF-beta 1, activates complement, and ultimately creates widespread inflammation across the brain, gut, hormones, immune system, and connective tissues.
The major pathological drivers identified in the condition research.
Mold species like Aspergillus, Stachybotrys, and Penicillium produce potent mycotoxins (trichothecenes, ochratoxin A, gliotoxin, and aflatoxins) that damage cell membranes, disrupt mitochondrial function, suppress immune response, and generate massive oxidative stress across multiple organ systems.
Approximately 24% of the population carries HLA-DR genotypes that prevent the immune system from properly tagging and clearing biotoxins. These individuals cannot form the antibodies needed to remove mycotoxins, leading to chronic recirculation and accumulation.
When biotoxins are not cleared, they trigger a cascading inflammatory response through the innate immune system. Cytokines rise, complement activation occurs, TGF-beta 1 and MMP-9 elevate, MSH drops, and VIP is suppressed, creating a self-perpetuating cycle of inflammation.
Mold illness is not a single-organ disease. Mycotoxins cross the blood-brain barrier causing neurological symptoms, disrupt gut barrier integrity triggering food sensitivities, suppress hormones, dysregulate the immune system, and impair detoxification pathways, making it one of the most complex multi-system conditions to treat.
14 patterns commonly associated with mold illness and cirs.
Where to deepen your research once you have the lay of the land.
In-depth articles covering mycotoxin exposure, biotoxin illness pathophysiology, mold remediation, detox protocols, and evidence-based recovery strategies for CIRS.
Browse articlesPremium chapters in the Junction Dysfunction Guide covering biotoxin pathways, HLA-DR genetics, binder protocols, immune dysregulation, and multi-system recovery from mold illness.
Explore chaptersTargeted lab panels to assess mycotoxin levels, inflammatory markers (TGF-beta 1, MMP-9, C4a), HLA-DR genotyping, MSH, VIP, and ADH levels.
View lab testsResearch on mycotoxins, biotoxin pathways, inflammatory markers, detoxification, and the nervous system response to mold exposure.
Key areas that evidence and clinical experience point to for meaningful recovery.
The foundation of any CIRS recovery protocol. Identifying and remediating the source of exposure, whether water-damaged buildings, contaminated food, or environmental reservoirs, is non-negotiable. No amount of supplementation will overcome ongoing exposure.
Cholestyramine (CSM), activated charcoal, bentonite clay, and chlorella bind mycotoxins in the gut and prevent reabsorption through enterohepatic recirculation. Glutathione, NAC, and phase II liver support accelerate systemic detoxification.
Addressing the dysregulated innate immune response with VIP nasal spray, low-dose naltrexone (LDN), omega-3 fatty acids, and targeted cytokine modulation. Restoring MSH and VIP levels is critical for breaking the inflammatory cascade.
MARCoNS colonization in the nasal passages is common in CIRS patients. BEG spray, nasal rinses, and biofilm disruptors target this persistent infection that blocks MSH recovery.
Common questions, with short evidence-backed answers.
CIRS is a multi-system inflammatory condition triggered by exposure to biotoxins, most commonly from water-damaged buildings. It was characterized by Dr. Ritchie Shoemaker and involves a cascade of immune dysregulation where genetically susceptible individuals cannot clear biotoxins.
Symptoms span multiple systems: neurological (brain fog, memory loss, word-finding difficulty, headaches), respiratory (chronic congestion, shortness of breath), musculoskeletal (muscle cramps, joint pain, weakness), visual (blurred vision, light sensitivity), and systemic (fatigue, night sweats, static shocks, metallic taste, temperature dysregulation).
Testing involves environmental assessment (ERMI/HERTSMI-2), mycotoxin urine testing, blood markers (C4a, TGF-beta-1, MMP-9, MSH, VIP, VEGF), HLA-DR genetic testing, and visual contrast sensitivity (VCS) testing.
The Shoemaker Protocol is a stepwise approach: remove from exposure, cholestyramine or Welchol binding therapy, correct MARCoNS, correct antigliadin antibodies, correct androgens, correct ADH/osmolality, correct MMP-9, correct VEGF, correct C3a, correct C4a, correct TGF-beta-1, then VIP nasal spray.
Evidence-based binders include cholestyramine (prescription, most studied), Welchol, activated charcoal, bentonite clay (aflatoxin-specific), chlorella, and zeolite clinoptilolite. Different mycotoxins respond to different binders.
Yes. Mycotoxins are neurotoxic and can cause peripheral neuropathy, autonomic dysfunction, cognitive impairment, and limbic system dysregulation. Many mold patients develop a cell danger response where the nervous system stays locked in a survival state.
HLA-DR is a gene that controls how your immune system identifies and removes foreign substances. About 24% of the population carries HLA-DR haplotypes that cannot properly tag and clear biotoxins. Without this clearance mechanism, biotoxins recirculate and trigger chronic inflammatory cascades.
Recovery varies. With proper treatment (removal from exposure + Shoemaker Protocol + supportive therapies), many people see improvement within 3-6 months. Full recovery can take 1-3 years depending on duration of exposure, genetic susceptibility, mold colonization, and co-infections.
Yes. Mycotoxins are potent mast cell activators. Chronic mold exposure can trigger mast cell activation syndrome (MCAS), leading to histamine intolerance, food sensitivities, flushing, and anaphylactoid reactions.
A low-mold diet avoids foods that contain or promote mycotoxins: aged cheeses, fermented foods, dried fruits, corn, peanuts, coffee, alcohol, and processed grains. Focus on fresh organic vegetables, clean proteins, healthy fats, and foods that support glutathione production.
Mold Illness and CIRS frequently travels alongside these conditions.
Jacob has worked with dozens of clients navigating mold illness and cirs. Pick the path that fits how you want to make progress today.